Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Within the last decade we have witnessed significant progress in the field of chromatin methylation, ranging from the discovery that chromatin methylation is reversible, to the identification of two classes of oxidative chromatin demethylases. Multiple genetic and cellular studies emphasize the role of members of the amine oxidase and 2-oxoglutarate oxygenase enzyme families involved in methyl-lysine in physiology and disease. Advances in understanding of the underlying biochemistry have resulted in development of first series of clinical inhibitors and tool compounds which continue to resolve and help understand the complex relationships between chromatin modification, control of gene expression and metabolic states.

Original publication

DOI

10.1016/j.cbpa.2016.06.021

Type

Journal article

Journal

Current opinion in chemical biology

Publication Date

08/2016

Volume

33

Pages

151 - 159

Addresses

Structural Genomics Consortium, University of Oxford, Headington OX3 7DQ, UK; Botnar Research Centre, NIHR Oxford Biomedical Research Unit, Oxford OX3 7LD, UK.

Keywords

Humans, Lysine, Histones, Enzyme Inhibitors, Genomics, Epigenesis, Genetic, Methylation, Catalysis, Clinical Trials as Topic, Histone Demethylases